CD38 and neoplasm: Consequently, inhibitors of CD203a/ENPP1 (26) could have anti-tumor activity by inhibiting the conversion of extracellular β-NAD+ to ADO and by inhibiting cGAMP degradation and, therefore, the secretion of SASP (senescent-associated secretory phenotype) factors which were found to increase CD38 expression (27, 28).